Using checklists and feedback to boost pneumonia vaccine uptake
Part of Infections clinical trials.
This study tests whether giving doctors regular information (based on checklists and vaccination records) will increase how many people get the pneumococcal vaccine. It focuses on people who are at higher risk for pneumococcal infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your GP practice is in the Flemish INTEGO network
- Your GP practice uses an electronic health record that links to the INTEGO database
- Your GP has signed the study consent form for the practice
- You are in a group recommended for the pneumococcal vaccine (based on Belgium guidance), such as certain high-risk conditions
- You have an electronic medical record in your GP’s practice that includes your health history and medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a pneumococcal vaccine (PCV-20) is safe and works well when given to adults during a fever. It may help protect people with certain health conditions from serious pneumococcal infections.
This study tests a new pneumonia vaccine (PCV13) in healthy infants to see if it works as well as a current vaccine. It compares the immune response and safety of the two vaccines.
This study tests a pneumococcal vaccine designed for 20 types of bacteria in older adults who are hospitalized with suspected community-acquired pneumonia. It aims to see how the vaccine works in real-world care and whether it affects how pneumonia happens or progresses.
This study looks at whether funding from the French National Health Insurance helps more people get recommended vaccines. It focuses on adults who need the pneumococcal vaccine and pregnant women who need the pertussis (whooping cough) vaccine.
This study looks at how to increase preventive care—especially flu and pneumonia vaccines—in people age 70 and older. It may help you get up to date on vaccines that can lower the risk of serious infections.
This trial tests a new 23-valent pneumococcal vaccine to see if it safely protects healthy people against pneumonia and other infections caused by pneumococcal bacteria.
Hear when a new Pneumococcal Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.